Changes in miRNA expression levels may contribute to various lung pathologies and diseases, including cystic fibrosis, chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis and lung cancer, by targeting many important signaling pathways, such as the TGF-β/SMAD signaling pathway, or by influencing HIF-1A related genes [9, 11–14]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.